Onco Actu du 31 mars 2015

Sommaire 3.1 Tabac E-cigarettes: Many teenagers trying them, survey concludes [BBC News] Scientists issue call for urgent controls on e-cigarette sales to children [The Guardian] Four in 10 teenage e-cigarette users would not have smoked, warn health experts [The Telegraph] 4. Dépistage, diagnostic et pronostic Cell Slime Could Hold Key to Cancer Detection [GEN] 4.5 Dép., diag. & prono. - Colorectal ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period [ASCO] 5. Traitements Researchers develop new potential drug for rare leukemia [University of Michigan Health System] More pieces in the prostate puzzle [The Cancer Blog] Generic cancer drugs that we can trust [Cancer World] 5.2 Pharma Novartis in major oncology drive [Pharmafile] 5.2.1 Pharma - Partenariats Merck KGaA forges a $941M CAR-T development deal with Intrexon [FierceBiotech] Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group [Novartis] CRT and Bioinvent expand collaboration with University of Southampton scientists to develop new immunotherapy treatments for cancer [Cancer Research UK] Novartis digs deeper into cancer with up to $750 million Aduro deal [Reuters] 5.3 Traitements - FDA, EMA,... FDA Approves First Therapy for High-Risk Neuroblastoma [National Cancer Institute] Breaking Down Barriers to Drug Innovation a Team Effort, FDA Says in Guidance [RAPS] 6. Lutte contre les cancers NIH forms team of experts to chart course for the President’s Precision Medicine Initiative research network [NIH] The Condition Cancer Research Is In [NY Times] 6.1 Observation Making Sense of Key Cancer Reports [National Cancer Institute] New analysis of breast cancer subtypes could lead to better risk stratification; Annual Report to the Nation shows that mortality and incidence for most cancers continue to decline [National Cancer Institute] U.S. cancer incidence, mortality largely stable or decreasing [Reuters] 6.10 Politiques Doctors With Cancer Push California To Allow Aid In Dying [NPR] 6.11 Patients ‘Can I go on a cruise?’ really means ‘How long do I have to live?’ [The Guardian] 6.4 Médico-éco Q&A: What can we learn from the US Choosing Wisely campaign to cut down unnecessary tests, treatment? [Croakey] 6.8 Communication “Cancer will always be in our midst:” A conversation with physician-writer Siddhartha Mukherjee [Scope Blog] A Week of Excitement and Hope: Communicating the Story of Cancer [National Cancer Institute] More than half of 60 Minutes devoted to "Killing Cancer" but still no independent perspective [HealthNewsReview] AACR Members Help Tell the Story of Cancer and Cancer Research in New Documentary [CANCER RESEARCH Catalyst] Chronicling Cancer Research in Books and Film [Dana-Farber Cancer Institute]

Les étoiles de couleur jaune signalent des articles dont la lecture est en priorité suggérée (1*) ou recommandée (3*). 3.1 Tabac E-cigarettes: Many teenagers trying them, survey concludes [BBC News] A ban on the sale of electronic cigarettes to under-18s has been announced in England and similar measures are being considered in England, Wales, Scotland and Northern Ireland. Scientists issue call for urgent controls on e-cigarette sales to children [The Guardian] But while the devices might help smokers quit their habit, some researchers are concerned that people will become addicted to the nicotine in e-cigarettes instead. The long term health consequences are vaping are not yet well known. Four in 10 teenage e-cigarette users would not have smoked, warn health experts [The Telegraph] A survey of 14 to 17-year-olds in the north west of England found that one in five had acquired e-cigarettes even though the government is bringing forward laws to ban their sale to under 18s. 4. Dépistage, diagnostic et pronostic Cell Slime Could Hold Key to Cancer Detection [GEN] As cells become cancerous, some proteins on their outer membranes shed sugar molecules and become less slimy, perhaps because they're crowded closer together. If we tune the MRI to detect sugars attached to a particular protein, we can see the difference between normal and cancerous cells. 4.5 Dép., diag. & prono. - Colorectal ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period [ASCO] Multi-Disciplinary Guidance Document Focuses on Using Molecular Markers to Optimize Patient Care. 5. Traitements Researchers develop new potential drug for rare leukemia [University of Michigan Health System] In a study published in Cancer Cell, the researchers tested two compounds they developed, MI-463 and MI-503, in cell lines and in mice with MLL leukemia. More pieces in the prostate puzzle [The Cancer Blog] When are the costs of surgery too great? It’s long been a burning question in prostate cancer, and papers presented over the past few days at the European Association of Urology’s conference in Madrid have added a few more pieces to the risk versus benefits jigsaw. Generic cancer drugs that we can trust [Cancer World] Generics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. It's good news for greater access, but patients want reassurance that switching to generics won’t put them at risk. 5.2 Pharma Novartis in major oncology drive [Pharmafile] Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat the disease. 5.2.1 Pharma - Partenariats Merck KGaA forges a $941M CAR-T development deal with Intrexon [FierceBiotech] Four months after Pfizer stepped up with a $2.85 billion promise to partner with Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma company has turned around to partner with Intrexon on an upstart CAR-T cancer drug development project. Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group [Novartis] Current approaches with checkpoint inhibitors and T-cell modulation are potent but only in select tumor types. STING agonists have the potential to fully activate the immune system to attack a broader range of tumors. CRT and Bioinvent expand collaboration with University of Southampton scientists to develop new immunotherapy treatments for cancer [Cancer Research UK] The program aims to develop new immunotherapy treatments for cancer based on preclinical work by the Southampton group showing the potential to treat cancer using antibodies targeting OX40 and 4-1BB – known ‘co-receptors’ that help stimulate the production of killer T-cells during an immune response. Novartis digs deeper into cancer with up to $750 million Aduro deal [Reuters] The move gives Novartis access to Aduro's experimental STING (Stimulator of Interferon Genes) technology, which is a next-generation method to harness the body's immune system to combat cancer. 5.3 Traitements - FDA, EMA,... FDA Approves First Therapy for High-Risk Neuroblastoma [National Cancer Institute] Dinutuximab is a monoclonal antibody that binds to a molecule known as GD2. This molecule, a ganglioside (a complex molecule that contains both lipids and carbohydrates), is expressed on the surface of neuroblastoma cells. Binding of dinutuximab to GD2 initiates an immune response that can kill the cells. Breaking Down Barriers to Drug Innovation a Team Effort, FDA Says in Guidance [RAPS] FDA's newly finalized guidance document, Critical Path Innovation Meetings, explains how stakeholders can set up meetings with FDA to discuss a methodology or technology which might enhance drug development. 6. Lutte contre les cancers NIH forms team of experts to chart course for the President’s Precision Medicine Initiative research network [NIH] Working Group to host public meetings, seek public input into the design of the Initiative. The Condition Cancer Research Is In [NY Times] In a letter to colleagues announcing his departure as the director of the National Cancer Institute, Dr. Harold Varmus, 75, quoted Mae West. “I’ve been rich and I’ve been poor,” he wrote, “and rich is better.” 6.1 Observation Making Sense of Key Cancer Reports [National Cancer Institute] This report is one of several regularly released reports that provide information on important cancer trends in the United States. New analysis of breast cancer subtypes could lead to better risk stratification; Annual Report to the Nation shows that mortality and incidence for most cancers continue to decline [National Cancer Institute] The new report suggests that some of the differences in rates of breast cancer incidence and mortality across racial and ethnic groups are related to differences in the incidence of different subtypes. U.S. cancer incidence, mortality largely stable or decreasing [Reuters] The analysis, published in the Journal of the National Cancer Institute, is the latest in a series of annual reports on cancer compiled since 1998 by the NAACCR, the ACS, the Centers for Disease Control and Prevention and the National Cancer Institute. 6.10 Politiques Doctors With Cancer Push California To Allow Aid In Dying [NPR] The right-to-die movement has gained renewed momentum in California and around the nation following the highly publicized death of Brittany Maynard. The 29-year-old with brain cancer moved from California to Oregon to take advantage of its "Death with Dignity" law and died in November after taking a fatal dose of barbiturates prescribed by her doctor. 6.11 Patients ‘Can I go on a cruise?’ really means ‘How long do I have to live?’ [The Guardian] “Doc, can I go on a cruise?” For someone who has never been on one, I have learnt a lot about cruises through being an oncologist. 6.4 Médico-éco Q&A: What can we learn from the US Choosing Wisely campaign to cut down unnecessary tests, treatment? [Croakey] When it launches next month, Choosing Wisely Australia® will start an important national conversation about reducing the many low value and often potentially harmful tests, treatments and procedures that have become entrenched in healthcare. 6.8 Communication “Cancer will always be in our midst:” A conversation with physician-writer Siddhartha Mukherjee [Scope Blog] Cancer will always be in our midst for one simple scientific reason: the very genes that allow us to grow and adapt, when mutated, lead to cancer. And these are not incidental genes – we are not talking about the periphery of human physiology – we are talking about the genes that function as the centerpieces of normal cellular growth and development. A Week of Excitement and Hope: Communicating the Story of Cancer [National Cancer Institute] The coming days will illustrate what I am referring to: how we communicate about the exciting work that is presently going on at NCI and in the cancer research community, but also about the future of cancer research and treatment. More than half of 60 Minutes devoted to "Killing Cancer" but still no independent perspective [HealthNewsReview] Unusual for a TV story, the anecdotes presented balanced positive findings with one cautionary tale in the form of a woman who underwent the procedure, became partially paralyzed, dropped out of the trial and died. AACR Members Help Tell the Story of Cancer and Cancer Research in New Documentary [CANCER RESEARCH Catalyst] More than 40 members of the AACR, including the AACR’s President-elect José Baselga, MD, PhD, and immediate Past President Charles Sawyers, MD, are featured in the documentary, along with 17 fellows of the AACR Academy. Chronicling Cancer Research in Books and Film [Dana-Farber Cancer Institute] “I was very impressed by how the filmmakers saw cancer as a problem in evolution – that’s not a new notion, but it’s important if you really want to understand the problem we’re facing now.”